Waldenstrom Macroglobulinemia
"Waldenstrom Macroglobulinemia" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A lymphoproliferative disorder characterized by pleomorphic B-LYMPHOCYTES including PLASMA CELLS, with increased levels of monoclonal serum IMMUNOGLOBULIN M. There is lymphoplasmacytic cells infiltration into bone marrow and often other tissues, also known as lymphoplasmacytic lymphoma. Clinical features include ANEMIA; HEMORRHAGES; and hyperviscosity.
| Descriptor ID |
D008258
|
| MeSH Number(s) |
C04.557.595.925 C14.907.454.960 C15.378.147.780.925 C15.378.463.515.960 C15.604.515.925 C20.683.780.925
|
| Concept/Terms |
Waldenstrom Macroglobulinemia- Waldenstrom Macroglobulinemia
- Macroglobulinemia, Waldenstrom
- Lymphoma, Lymphoplasmacytoid
- Lymphomas, Lymphoplasmacytoid
- Lymphoplasmacytoid Lymphoma
- Lymphoplasmacytoid Lymphomas
- Macroglobulinemia
- Waldenstrom's Macroglobulinemia
- Macroglobulinemia, Waldenstrom's
- Waldenstroms Macroglobulinemia
- Waldenstrom's Macroglobulinaemia
- Macroglobulinaemia, Waldenstrom's
- Waldenstrom Macroglobulinaemia
- Waldenstroms Macroglobulinaemia
- Lymphoma, Lymphocytic, Plasmacytoid
- Primary Macroglobulinemia
- Macroglobulinemia, Primary
Familial Waldenstrom's Macroglobulinaemia- Familial Waldenstrom's Macroglobulinaemia
- Familial Waldenstrom Macroglobulinaemia
- Familial Waldenstroms Macroglobulinaemia
- Macroglobulinaemia, Familial Waldenstrom's
- Waldenstrom's Macroglobulinaemia, Familial
|
Below are MeSH descriptors whose meaning is more general than "Waldenstrom Macroglobulinemia".
Below are MeSH descriptors whose meaning is more specific than "Waldenstrom Macroglobulinemia".
This graph shows the total number of publications written about "Waldenstrom Macroglobulinemia" by people in this website by year, and whether "Waldenstrom Macroglobulinemia" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2009 | 2 | 0 | 2 |
| 2011 | 1 | 0 | 1 |
| 2014 | 6 | 0 | 6 |
| 2015 | 8 | 0 | 8 |
| 2016 | 17 | 1 | 18 |
| 2017 | 9 | 1 | 10 |
| 2018 | 23 | 0 | 23 |
| 2019 | 7 | 0 | 7 |
| 2020 | 10 | 0 | 10 |
| 2021 | 14 | 0 | 14 |
| 2022 | 11 | 0 | 11 |
| 2023 | 8 | 0 | 8 |
| 2024 | 8 | 1 | 9 |
| 2025 | 13 | 0 | 13 |
| 2026 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Waldenstrom Macroglobulinemia" by people in Profiles.
-
Safety and activity of pirtobrutinib in patients with relapsed or refractory Waldenstr?m macroglobulinaemia: 5-year follow-up of the open-label, multicentre, phase 1/2 BRUIN trial. Lancet Haematol. 2026 May; 13(5):e284-e296.
-
POD24 is a novel determinant of prognosis in patients with Waldenstr?m macroglobulinemia. Blood Adv. 2026 Apr 14; 10(7):2322-2327.
-
Final Report of a Phase II Study of Ibrutinib and Venetoclax in Previously Untreated Waldenstr?m Macroglobulinemia. Am J Hematol. 2026 Jun; 101(6):1255-1263.
-
Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenstr?m Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications. Am J Hematol. 2026 May; 101(5):1045-1055.
-
Familial clusters and clinical features, complications, and outcomes in 1000 patients with Waldenstr?m macroglobulinemia. Blood Adv. 2026 Jan 27; 10(2):334-342.
-
Clinicopathological features and management of IgM multiple myeloma and Waldenstrom macroglobulinemia. Leuk Lymphoma. 2026 Apr; 67(5):989-996.
-
BCL-2 inhibition in Waldenstr?m macroglobulinaemia and marginal zone lymphoma. Br J Haematol. 2025 Dec; 207(6):2261-2269.
-
Long-term follow-up of venetoclax monotherapy in previously treated patients with Waldenstr?m macroglobulinemia. Blood Adv. 2025 Oct 14; 9(19):4842-4847.
-
Ibrutinib plus rituximab vs ibrutinib monotherapy in patients with Waldenstr?m macroglobulinemia: a pooled analysis. Blood Adv. 2025 Sep 23; 9(18):4705-4715.
-
Prospective study of immunogenicity to SARS-CoV-2 booster vaccines in multiple myeloma and Waldenstr?m macroglobulinemia. Blood Adv. 2025 Sep 23; 9(18):4568-4579.